Antibiotice
Știință și suflet

CURRENT REPORT

Report date: **13.11.2026**
Name of issuing company: **Antibiotice S.A.**
Headquarters: **Iași, str. Valea Lupului nr. 1, zip code 707410**
https://www.antibiotice.ro
E-mail: **relatiicuinvestitorii@antibiotice.ro**
Telephone/fax no. : **+40232 209 000 / +40372 065 633**
Unique registration code in the Trade Register Office: **RO1973096**
No. in the Trade Register: **J1991000285223**
Subscribed and paid-up capital: **67,133,804 LEI**
The regulated market trading on which the securities are issued**: Bucharest Stock Exchange**
Number of shares: **671,338,040**
Number of votes: **671,338,040**
Main characteristics of the securities issued by the company**: nominative shares, nominal value: 0.10 lei**

Important event to report:

Changes in the Executive Management of Antibiotice S.A.

Antibiotice S.A. informs its shareholders and investors that, at its meeting held on 12 November 2026, the Board of Directors adopted a number of decisions to ensure continuity in the Company's executive management. These decisions follow the steps announced in the current report dated 30 October 2026.

Chief Executive Officer

Following Mr Ioan Nani's resignation from his positions as Chief Executive Officer and Executive Director, the Board of Directors appointed Mr Mircea-Bogdan Babici as Interim Chief Executive Officer, effective 4 December 2026, for a period of up to five months.

At the same meeting, the Board initiated the selection procedure for the Chief Executive Officer, pursuant to Government Emergency Ordinance No. 109/2011 on the corporate governance of public enterprises. The selected Chief Executive Officer will serve a term ending on 15 April 2029. The interim term will end upon completion of the procedure, when the Board appoints the Chief Executive Officer.

Mr Mircea-Bogdan Babici has been a member of the Antibiotice management team since May 2026, serving as Deputy Chief Executive Officer. He holds a doctorate in economics and has over 25 years of management experience in the financial and banking sector. Within the Company, he oversees finance, corporate governance, risk management, cybersecurity and digital transformation, areas that are important to the Company's financial stability and the pace of ongoing investment projects. His appointment ensures continuity in the approved strategy and development plans, without interruption to executive management.

Board of Directors

To fill the vacant director position, the Board of Directors has convened the Ordinary General Meeting of Shareholders for 17 December 2026. The agenda includes the election of an interim director and the initiation of the selection procedure for a permanent director. The convening notice and supporting materials will be published within the time limits and under the conditions prescribed by law.

Chief Financial Officer

Following the retirement of Ms Paula Luminița Coman, who served as the Company's Chief Financial Officer for the past 15 years, the Board of Directors appointed Ms Mihaela Nitu as Interim Chief Financial Officer, effective 14 November 2026, for a period of up to five months. The Board also initiated the selection procedure for the Chief Financial Officer, whose term will end on 15 April 2029. In this case as well, the interim term will end upon completion of the procedure, when the Board appoints the Chief Financial Officer.

Ms Mihaela Nitu has over 17 years of experience in finance and accounting, including 11 years at Antibiotice, with the last seven spent coordinating financial operations and economic analysis. As Executive Finance Manager, she was responsible for budgeting, cash flow and working capital, banking relationships, and financing the Company's operations and investments. She is a certified accountant and holds postgraduate qualifications in auditing, accounting management and business taxation. Her detailed knowledge of the Company and the pharmaceutical industry enables her to assume the role without a transition period.

The Board of Directors thanks Mr Ioan Nani for his years of leadership at Antibiotice. Under his leadership, the Company modernised its operations, expanded its presence in international markets and strengthened its position in the pharmaceutical industry.

The Board also thanks Ms Paula Luminița Coman for her 15 years at the helm of the Company's finance function. She maintained the Company's financial stability and secured the resources required for its development projects.

Antibiotice S.A. will keep the market informed, through current reports, of progress in the selection procedures, resolutions adopted by the General Meeting of Shareholders and any other relevant developments.

President of the Board of Directors,
Ionuț-Sebastian IAVOR